These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 18717215)
1. Hypertrophic cardiomyopathy--state of the art in 2007. Monteiro S; Costa S; Monteiro P; Gonçalves L; Providência LA Rev Port Cardiol; 2008 May; 27(5):625-37. PubMed ID: 18717215 [TBL] [Abstract][Full Text] [Related]
2. Sudden death and hypertrophic cardiomyopathy: a review. Ly HQ; Greiss I; Talakic M; Guerra PG; Macle L; Thibault B; Dubuc M; Roy D Can J Cardiol; 2005 Apr; 21(5):441-8. PubMed ID: 15861263 [TBL] [Abstract][Full Text] [Related]
3. Risk stratification of sudden cardiac death in hypertrophic cardiomyopathy. Miller MA; Gomes JA; Fuster V Nat Clin Pract Cardiovasc Med; 2007 Dec; 4(12):667-76. PubMed ID: 18033231 [TBL] [Abstract][Full Text] [Related]
4. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692 [TBL] [Abstract][Full Text] [Related]
5. Malignant mutations in hypertrophic cardiomyopathy: fact or fancy? Brito D; Madeira H Rev Port Cardiol; 2005 Sep; 24(9):1137-46. PubMed ID: 16335287 [TBL] [Abstract][Full Text] [Related]
6. Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy. Limongelli G; Elliott PM; Pacileo G; Sarubbi B; Thaman R; Calabrò P; Vergara P; Iacomino M; Russo MG; Calabrò R J Cardiovasc Med (Hagerstown); 2006 Sep; 7(9):711-3. PubMed ID: 16932087 [TBL] [Abstract][Full Text] [Related]
8. The pathology of hypertrophic cardiomyopathy. Hughes SE Histopathology; 2004 May; 44(5):412-27. PubMed ID: 15139989 [TBL] [Abstract][Full Text] [Related]
9. Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. Mogensen J; Murphy RT; Kubo T; Bahl A; Moon JC; Klausen IC; Elliott PM; McKenna WJ J Am Coll Cardiol; 2004 Dec; 44(12):2315-25. PubMed ID: 15607392 [TBL] [Abstract][Full Text] [Related]
10. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596 [TBL] [Abstract][Full Text] [Related]
11. Advances in the prevention of sudden cardiac death in the young. Shephard R; Semsarian C Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):145-55. PubMed ID: 19144665 [TBL] [Abstract][Full Text] [Related]
12. [Therapy and risk-stratification in hypertrophic cardiomyopathy--a current survey]. Reith S; Klues HG Z Kardiol; 2003 Apr; 92(4):283-93. PubMed ID: 12707787 [TBL] [Abstract][Full Text] [Related]
13. [Use of an implantable defibrillator for the prevention of sudden death in hypertrophic cardiomyopathy]. Hentati M; Ben Ameur I; Kechida Z; Charfeddine H; Hached L; Grati Z; Kammoun S Tunis Med; 2003; 81 Suppl 8():675-9. PubMed ID: 14608758 [TBL] [Abstract][Full Text] [Related]
14. Hypertrophic cardiomyopathy in a Portuguese population: mutations in the myosin-binding protein C gene. Cardim N; Perrot A; Santos S; Morgado P; Pádua M; Ferreira S; Reis RP; Monteiro C; Ferreira T; Correia JM; Osterziel KJ Rev Port Cardiol; 2005 Dec; 24(12):1463-76. PubMed ID: 16566405 [TBL] [Abstract][Full Text] [Related]
15. Syncope, other risk factors, and the implantable defibrillator for sudden death prevention in hypertrophic cardiomyopathy. Cotiga D; Ehlert F; Sherrid M Anadolu Kardiyol Derg; 2006 Dec; 6 Suppl 2():55-60. PubMed ID: 17162272 [TBL] [Abstract][Full Text] [Related]
16. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy. Maron BJ; Spirito P J Cardiovasc Electrophysiol; 2008 Oct; 19(10):1118-26. PubMed ID: 18384577 [TBL] [Abstract][Full Text] [Related]
17. Hypertrophic cardiomyopathy and sudden death: new perspectives on risk stratification and prevention with the implantable cardioverter-defibrillator. Maron BJ Eur Heart J; 2000 Dec; 21(24):1979-83. PubMed ID: 11102243 [No Abstract] [Full Text] [Related]
18. Systematic analysis of the regulatory and essential myosin light chain genes: genetic variants and mutations in hypertrophic cardiomyopathy. Kabaeva ZT; Perrot A; Wolter B; Dietz R; Cardim N; Correia JM; Schulte HD; Aldashev AA; Mirrakhimov MM; Osterziel KJ Eur J Hum Genet; 2002 Nov; 10(11):741-8. PubMed ID: 12404107 [TBL] [Abstract][Full Text] [Related]
19. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. Decker JA; Rossano JW; Smith EO; Cannon B; Clunie SK; Gates C; Jefferies JL; Kim JJ; Price JF; Dreyer WJ; Towbin JA; Denfield SW J Am Coll Cardiol; 2009 Jul; 54(3):250-4. PubMed ID: 19589438 [TBL] [Abstract][Full Text] [Related]
20. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]